Table 2.
Characteristics of 58 AAV patients followed by the Rheumatology Clinic of Udine (2010–2018)
| Demography | |
|---|---|
| Age, years | 57.8 ± 14.3 |
| Female gender | 34 (58.6%) |
| AAV diagnosis | |
| GPA | 30 (51.7%) |
| EGPA | 19 (32.8%) |
| MPA | 9 (15.5%) |
| BVAS v3 | 13.9 ± 6.7 |
| Baseline vasculitis involvement | |
| Constitutional symptoms | 47 (81%) |
| ENT | 35 (60.3%) |
| Lungs | 29 (50%) |
| Kidney | 19 (32.8%) |
| Nervous system | 19 (32.8%) |
| Skin | 19 (32.8%) |
| Cardiovascular | 6 (10.3%) |
| Gastrointestinal | 6 (10.3%) |
| Eye | 2 (3.4%) |
| ANCA status | |
| Positive ANCA | 47 (81%) |
| cANCA/PR3 | 24 (51.1%) |
| pANCA/MPO | 23 (48.9%) |
AAV ANCA-associated vasculitis, GPA granulomatosis with polyangiitis, EGPA eosinophilic granulomatosis with polyangiitis, MPA micropolyangiitis, BVAS Birmingham Vasculitis Activity Score, ENT ear-nose-throat involvement, ANCA anti-neutrophil cytoplasmic antibodies, PR3 proteinase 3, MPO myeloperoxidase. Variables are reported as mean ± SD or N (%)